Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting

• Published in: Annals of Thoracic and Cardiovascular Surgery 2019, Vol.25(1), pp.26-31
• Main Authors: Tamura, Kiyoshi, Maruyama, Toshiyuki, Sakurai, Syogo
• Format: Article
• Language: English
• Subjects: coronary artery bypass grafting; orexin receptor antagonist; Original; postoperative delirium; Suvorexant
• ISSN: 1341-1098; 2186-1005
• DOI: 10.5761/atcs.oa.18-00038

Objective: Suvorexant is an orexin receptor antagonist and is effective in inducing sleep. We hypothesized that Suvorexant would reduce the incidence of postoperative delirium (POD) after coronary artery bypass grafting (CABG).Methods: We reviewed 88 patients (12 women, mean age: 69.3 ± 2.5 years) who were undergone CABG alone. Patients were divided into two groups; patients received Suvorexant (S group, n = 36), patients not received Suvorexant (N group, n = 52), and the following data were analyzed and compared between two groups.Results: Intensive Care Unit Delirium Screening Checklist Score was significantly lower in S group compared with N group (N:S = 2.0 ± 1.7:0.8 ± 1.0, p = 0.0003). Although POD was present in 11 of 52 patients (21.2%) in N group, one patient (2.8%) developed in S group (p = 0.008). In S group, both intensive care unit stay (N:S = median 6:5 days, p = 0.001) and hospital stay (N:S = median 23:20 days, p = 0.035) were significantly shorter than in N group.Conclusions: Suvorexant might reduce incidence of POD in patients undergone CABG.